You are on the new improved site. You can view the old site in view-only mode here until June 27, 2026

Filter Results

Search all journals

Enter search terms…

Advanced search

/

About

About Sage
About Sage Journals
Privacy Policy
Terms of Use
Contact Us
Help

Information for

Authors
Editors
Librarians
Researchers
Reviewers
Frequently asked questions

Copyright © 2026 by Sage Publications.京ICP备09090397号-11

Search results

Search results page

Articles (173)

Journals (0)

1-10 of 173 results for HR /HER2 breast cancer

Sort by:

Relevance

Select all

Select all

Sort by:

Relevance

Select article: Evolving perspectives on the treatment of HR+/HER2+ metastatic breast cancer

Open access

Review article

First published 2023

Evolving perspectives on the treatment of HR+/HER2+ metastatic breast cancer

Mark Pegram, Richard Pietras, Chau T. Dang [...]

Therapeutic Advances in Medical Oncology

Select article: Ribociclib in HR+/HER2− Advanced or Metastatic Breast Cancer Patients

Retricted access

Review article

First published 2019-5

Ribociclib in HR+/HER2− Advanced or Metastatic Breast Cancer Patients

Kaitlin Rascon, Goran Flajc, Carmine De Angelis [...]

Annals of Pharmacotherapy

Select article: Clinical Outcomes with First-line Endocrine Therapy or Chemotherapy in Postmenopausal HR+/HER2-Metastatic Breast Cancer

Open access

Research article

First published 2015

Clinical Outcomes with First-line Endocrine Therapy or Chemotherapy in Postmenopausal HR+/HER2-Metastatic Breast Cancer

Yan Song, Yanni Hao, Alexander R. Macalalad [...]

Breast Cancer: Basic and Clinical Research

Select article: Economic Evaluation of Inavolisib Combined With Palbociclib–Fulvestrant for PIK3CA-Mutated,HR+/HER2− Advanced Breast Cancer in USA

Open access

Research article

First published 2026

Economic Evaluation of Inavolisib Combined With Palbociclib–Fulvestrant for PIK3CA-Mutated,HR+/HER2− Advanced Breast Cancer in USA

Hanqing Zeng, Li-Ying Song, Ren Guo [...]

Technology in Cancer Research & Treatment

Select article: Rationale and trial design of NATALEE: a Phase III trial of adjuvant ribociclib + endocrine therapy versus endocrine therapy alone in patients with HR+/HER2− early breast cancer

Open access

Research article

First published 2023

Rationale and trial design of NATALEE: a Phase III trial of adjuvant ribociclib + endocrine therapy versus endocrine therapy alone in patients with HR+/HER2− early breast cancer

Dennis J. Slamon, Peter A. Fasching, Sara Hurvitz [...]

Therapeutic Advances in Medical Oncology

Select article: Endocrine therapy plus HER2-targeted therapy,another favorable option for HR+/HER2+ advanced breast cancer patients

Open access

Review article

First published 2024

Endocrine therapy plus HER2-targeted therapy,another favorable option for HR+/HER2+ advanced breast cancer patients

Yuehua Liang, Xiaoran Liu, Zehui Yun [...]

Therapeutic Advances in Medical Oncology

Select article: Comparison of neoadjuvant chemotherapy response and prognosis among pegylated liposomal doxorubicin,epirubicin and pirarubicin in HR ⩽ 10%/HER2-negative breast cancer: an exploratory real-world multicentre cohort study

Open access

Research article

First published 2024

Comparison of neoadjuvant chemotherapy response and prognosis among pegylated liposomal doxorubicin,epirubicin and pirarubicin in HR ⩽ 10%/HER2-negative breast cancer: an exploratory real-world multicentre cohort study

Yue Hong, Jing Peng, Qitong Chen [...]

Therapeutic Advances in Medical Oncology

Select article: Advances in the mechanism of CDK4/6 inhibitor resistance in HR+/HER2− breast cancer

Open access

Review article

First published 2024

Advances in the mechanism of CDK4/6 inhibitor resistance in HR+/HER2− breast cancer

Sijia Wu, Junnan Xu, Yiwen Ma [...]

Therapeutic Advances in Medical Oncology

Select article: TROPION-Breast04: a randomized phase III study of neoadjuvant datopotamab deruxtecan (Dato-DXd) plus durvalumab followed by adjuvant durvalumab versus standard of care in patients with treatment-naïve early-stage triple negative or HR-low/HER2− breast cancer

Open access

Research article

First published 2025

TROPION-Breast04: a randomized phase III study of neoadjuvant datopotamab deruxtecan (Dato-DXd) plus durvalumab followed by adjuvant durvalumab versus standard of care in patients with treatment-naïve early-stage triple negative or HR-low/HER2− breast cancer

Heather L. McArthur, Sara M. Tolaney, Rebecca Dent [...]

Therapeutic Advances in Medical Oncology

Select article: Dalpiciclib in combination with letrozole/anastrozole or fulvestrant in HR-positive and HER2-negative advanced breast cancer: results from a phase Ib study

Open access

Research article

First published 2024

Dalpiciclib in combination with letrozole/anastrozole or fulvestrant in HR-positive and HER2-negative advanced breast cancer: results from a phase Ib study

Qingyuan Zhang, Pin Zhang, Min Yan [...]

Therapeutic Advances in Medical Oncology

1
2
3
•••
18
10 / page

Article type

Publication date

Subjects

Access